Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
N/A N=47 Randomized Triple-blind Basic Science

At-home Transcranial Alternating Current Stimulation During Multitasking

Multitasking Behavior

Bottom Line

View on ClinicalTrials.gov: NCT04231825 ↗
Enrolled (actual)
47
Serious AEs
0.0%
Results posted
Oct 2021
Primary outcome: Primary: Multitasking Performance Cost (Neuroracer Performance Change From Baseline) — 45.3; 37.9 percentage change of d' — p=0.55

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Transcranial alternating current stimulation (Device)
Age
Adult · 18+ yrs
Sex
All
Sponsor
University of California, San Francisco
Primary completion
Aug 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Multitasking Performance Cost (Neuroracer Performance Change From Baseline)		 45.3; 37.9 0.55
PRIMARY
Single Task Performance Change		 1.99; 2.70 0.02 sig
PRIMARY
Multitask Performance Change		 1.17; 1.79 0.03 sig
SECONDARY
Continuous Performance Test RT Change (Test of Visual Attention / Sustained Attention)		 300; 303 0.51
SECONDARY
Continuous Performance Test RTV Change (Test of Visual Attention / Sustained Attention)		 58; 56 0.80

Summary

The goal is to replicate in-lab results from transcranial alternating current stimulation (tACS) with at-home tACS.

Eligibility Criteria

Inclusion Criteria

  • English speaking
  • Grade 12 or more education
  • Normal or corrected to normal vision and hearing
  • Ability to complete cognitive tasks
  • Ability to cooperate and comply with all study procedures
  • Ability to tolerate tACS

Exclusion Criteria

  • Neurological or psychiatric disorders
  • Family history of epilepsy
  • History of seizures
  • Prior head trauma
  • Pregnant
  • Implanted electronic devices (e.g., pacemaker)
  • IQ < 80
  • Taking psychotropic medication
  • Taking anti-depressants or anti-anxiety medication
  • Substance abuse
  • Color blind
  • Glaucoma
  • Macular degeneration
  • Amblyopia
  • Strabismus
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04231825). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search